Polaris Market Research today released findings from its latest report, projecting the global oral solid dosage contract manufacturing market to grow from USD 10.99 billion in 2026 to USD 22.62 billion by 2034, at a CAGR of 9.4%. The market was valued at USD 10.07 billion in 2025. The report profiles 15 leading companies across three market segments.

Oral solid dosage forms such as tablets and capsules remain the backbone of prescription medicine, accounting for roughly two-thirds of drugs dispensed worldwide. As active pharmaceutical ingredients grow more complex, pharmaceutical companies are increasingly relying on contract development and manufacturing organizations (CDMOs) to scale production, manage costs, and speed products to market.

Analyst Commentary on Oral Solid Dosage Contract Manufacturing Market Growth

"Pharmaceutical companies are leaning harder on CDMOs to control costs, speed time-to-market, and access specialized tablet and capsule manufacturing capacity" said an analyst at Polaris Market Research. "Buyers should prioritize partners investing in continuous manufacturing and containment capabilities for complex, high-potency formulations."

Oral Solid Dosage Contract Manufacturing Market Statistics at a Glance

• 2026 Market Estimate: USD 10.99 Billion
• 2034 Projected Market Size: USD 22.62 Billion
• CAGR (2026-2034): 9.4%
• North America held 41.20% of global revenue in 2025; Asia-Pacific is projected to grow fastest at 11.80% CAGR

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: Rising pharmaceutical outsourcing as drugmakers seek to reduce capital costs and reach the market faster, growing generic drug demand tied to patent expirations, and advances in drug-delivery technology are the primary forces behind the market's expansion, alongside rising demand for controlled-release formulations, which captured 43.50% of 2025 revenue. In August 2025, Piramal Pharma Solutions and NewAmsterdam Pharma opened a dedicated oral solid dosage suite in Pennsylvania to expand fixed-dose combination manufacturing.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/oral-solid-dosage-contract-manufacturing-market

Major Companies Covered: Catalent, Inc., Lonza, Piramal Pharma Solutions, Recipharm AB, Pfizer CentreOne.

Segments Covered: By Product (Tablets, Capsules, Granules, Powder, Others), By Mechanism (Controlled Release, Immediate Release, Delayed Release), By End-User, By Region.

Tablets represented 33.10% of 2025 revenue, supported by low manufacturing costs and broad clinical use, while capsules are projected to grow fastest at a 10.80% CAGR through 2034 thanks to easier swallowing and faster disintegration. Controlled-release formulations held 43.50% of 2025 revenue as demand grows for sustained, steady drug delivery.

Additional Driver: Generic Drug Demand and Patent Expirations: A wave of patent expirations is fueling demand for generic tablets and capsules, and CDMOs are stepping in to help drug companies scale production efficiently. Large-scale manufacturers with proven regulatory track records are seeing particularly strong demand as pharmaceutical companies prioritize compliance and reliability when selecting outsourcing partners.

Recent Developments in the Oral Solid Dosage Contract Manufacturing Market

• March 2026: Forma Life Sciences launched as an independent CDMO focused on oral solid dosage development and manufacturing in the U.S., backed by two cGMP facilities.
• February 2026: Piramal Pharma Solutions introduced commercial tablet-in-capsule technology supporting dual-release and combination drug formulations.
• August 2025: Piramal Pharma Solutions and NewAmsterdam Pharma invested in a dedicated Pennsylvania facility to expand oral solid dosage capabilities.

Regional Snapshot: North America Leads Revenue, Asia-Pacific Grows Fastest

North America accounted for 41.20% of global market revenue in 2025, driven by rising investment in drug development and clinical research across the U.S. and Canada. Asia-Pacific is expected to post the fastest growth of the forecast period, at an 11.80% CAGR, on the back of strong manufacturing capacity and rising pharmaceutical outsourcing to India, China, and Singapore.

Market Outlook

Looking ahead, continued outsourcing by pharmaceutical companies, growth in generic and complex formulations, and expanding regional manufacturing capacity are expected to sustain momentum in the oral solid dosage contract manufacturing market through 2034, with strategic alliances between drugmakers and CDMOs likely to shape the competitive landscape.

Why It Matters for CDMO Partner Selection for Oral Solid Dosage Manufacturing

For stakeholders researching cdmo partner selection for oral solid dosage manufacturing, the underlying report benchmarks oral solid dosage contract manufacturing market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034. Beyond headline figures, the analysis is designed to help procurement teams, investors, and strategy leads translate market-size and growth-rate data into concrete sourcing, budgeting, and go-to-market decisions.

Report Coverage

The report examines the oral solid dosage contract manufacturing market across product, mechanism, end-user, and region, alongside company profiles covering financial performance, product benchmarking, and recent developments, offering a complete view of the competitive landscape through 2034.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

mushroom-market

microplastic-filtration-systems-market

algae-based-sustainable-aviation-fuel-market

us-wind-turbine-market

erythropoietin-drugs-market

sensitive-compartmented-information-facility-market

paprika-oleoresin-market

us-plant-based-meat-market

how-biometric-authentication-is-reshaping-mobile-banking-security